Trabectedin
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TRABECTEDIN |
|---|---|
| Type | Drug |
| Aliases | ET-743Ecteinascidin-743YondelisТрабектедин |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-OVARIAN |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 SRC-OVA-301-MONK-2010 |
Drug Facts
| Class | Marine-derived alkylating agent (tetrahydroisoquinoline alkaloid; minor-groove DNA binder) |
|---|---|
| Mechanism | Binds the minor groove of DNA at guanine N2, bending the helix toward the major groove and inducing transcription-coupled nucleotide-excision repair–dependent DNA double-strand breaks. Modulates the tumor microenvironment by depleting tumor-associated macrophages. |
| Typical dosing | Sarcoma (single-agent): 1.5 mg/m² IV over 24 h every 21 days via central line, with mandatory dexamethasone 20 mg IV 30 min pre-dose. Ovarian (with PLD per OVA-301): 1.1 mg/m² IV over 3 h every 21 days given immediately after PLD 30 mg/m². |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Ovarian: OVA-301 (Monk et al., JCO 2010, PMID 20194850) — phase 3 trabectedin + PLD vs PLD alone in relapsed ovarian; PFS 7.3 vs 5.8 mo overall (HR 0.79); benefit greatest in partially-platinum-sensitive (PFI 6-12 mo) subgroup. Mandatory premedication with dexamethasone reduces hepatic and emetogenic toxicity. Central line required. Cumulative cardiotoxicity risk additive to anthracycline exposure — baseline and serial LVEF monitoring mandatory in PLD combination.
Used By
Regimens
REG-TRABECTEDIN-PLD-OVARIAN- Trabectedin + PLD (recurrent ovarian, OVA-301)